Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26247647 | 0.76 | ALDH1A1 (0.40) | FAAHMGLLALDH1A1LMNATDP1 | |
| SCHEMBL9544194 | 0.76 | TSHR (0.36) | FAAHMGLLALDH1A1LMNATDP1 | |
| SCHEMBL6864349 | 0.76 | TSHR (0.45) | FAAHMGLLALDH1A1LMNATSHR | |
| SCHEMBL9544187 | 0.76 | TSHR (0.36) | FAAHMGLLALDH1A1LMNATDP1 | |
| SCHEMBL15540840 | 0.75 | LMNA (0.59) | FAAHMGLLALDH1A1LMNATSHR | |
| SCHEMBL9625539 | 0.74 | ALDH1A1 (0.36) | FAAHMGLLALDH1A1LMNA | |
| SCHEMBL28398511 | 0.74 | TSHR (0.48) | FAAHMGLLALDH1A1LMNATDP1 | |
| SCHEMBL19821996 | 0.74 | CTSL (0.37) | FAAHCTSLCTSBCTSKLMNA | |
| SCHEMBL12085801 | 0.73 | ALDH1A1 (0.38) | FAAHMGLLALDH1A1LMNATDP1 | |
| SCHEMBL22492586 | 0.73 | ALDH1A1 (0.38) | FAAHMGLLALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2022-07-21 | — | — | US | disclosed |
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210002211-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3717453-A2 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Ultragenyx Pharmaceutical Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, PYGM, TKT | FAAH 2469/4885MGLL 1136/4885CTSL 724/4885 |
| US-20210002211-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | FAAH 2469/4885MGLL 1136/4885CTSL 724/4885 |
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | FAAH 2469/4885MGLL 1136/4885CTSL 724/4885 |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, PYGM, TKT | FAAH 2469/4885MGLL 1136/4885CTSL 724/4885 |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | FAAH 2469/4885MGLL 1136/4885CTSL 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.